Stocks making the biggest moves premarket: Palantir Technologies, Ford Motor, Vertex Pharmaceuticals, DoorDash and more
These are some of the stocks posting the largest moves in premarket trading
Check out the companies making headlines before the bell. Palantir Technologies – The defense technology stock fell more than 8% after it earned an adjusted 13 cents per share in the first quarter, matching analyst expectations, according to LSEG, while revenue of $884 million topped the $863 million that analysts were looking for. Palantir also boosted its full-year revenue guidance, but FactSet's StreetAccount cited a "lower magnitude of Q1 beat, weaker Europe, slowing customer growth rates, tariffs/trade tensions, and valuation" as causes of the decline. Ford Motor – The F-series pickup truck maker fell more than 2% after it suspended its 2025 guidance , citing "near-term risks, especially the potential for industrywide supply chain disruption impacting production." First-quarter earnings and auto revenue came in better than expected. Other automakers also fell premarket, with General Motors and Stellantis dropping 0.3% and almost 2%, respectively. Tesla moved down nearly 2%. Neurocrine Biosciences – Shares of the biopharmaceutical company jumped nearly 10% after its $572.6 million in revenue for the first quarter topped the $559.6 million that analysts polled by FactSet were expecting. Additionally, sales of Ingrezza, a medication used to treat movement disorders, gained 8% year over year to $545 million. Celsius Holdings – The energy drink maker's stock slid 5.6% on the back of weak first-quarter earnings. Celsius earned 15 cents per share on a GAAP basis, missing the consensus forecast of analysts polled by FactSet by 5 cents a share. Revenue came in at $329.3 million, while Wall Street had penciled in $344.2 million. Hims & Hers Health – Shares lost 6% after the company guided for lighter-than-expected revenue in its second quarter. The telehealth provider forecast revenue to come in between $530 million to $550 million, missing the $564.6 million that analysts polled by FactSet had penciled in. Hims & Hers first-quarter earnings and revenue both beat Street estimates. Vertex Pharmaceuticals – The biotech stock tumbled more than 5% on the heels of weaker-than-expected quarterly results, with adjusted earnings of $4.06 per share below the $4.25 consensus estimate, according to FactSet. Revenue came in at $2.77 billion, missing the consensus estimate of $2.86 billion. Upwork – The stock jumped 10% after the freelance marketplace platform posted first-quarter adjusted earnings of 34 cents per share on revenue of $192.7 million, beating the 27 cents a share on revenue of $188.5 million expected by analysts polled by FactSet. Upwork also raised its full-year adjusted earnings guidance to $1.14 to $1.18 per share from $1.05 to $1.10 a share, also topping analyst estimates. Clorox – The cleaning product maker slid almost 3% after posting disappointing results in its fiscal third quarter, when it earned an adjusted $1.45 per share on revenue of $1.67 billion, short of the $1.57 per share and $1.73 billion in revenue analysts were estimating, according to LSEG. Lattice Semiconductor – The chip stock slipped more than 2% after first-quarter results roughly matched expectations. Adjusted earnings per share of 22 cents were in-line with analyst estimates, according to FactSet, while revenue of $120.2 million compared to an estimate of $120.1 million. Lattice's revenue, net income and gross margin were all down year over year from the same period in 2024. DoorDash – Shares declined more than 3% after first-quarter revenue missed analyst estimates. Adjusted earnings, however, topped expectations. DoorDash also announced a $1.2 billion acquisition of restaurant booking platform SevenRooms, which comes on the heels of British food delivery service Deliveroo also agreeing to a takeover offer from DoorDash. — CNBC's Alex Harring, Jesse Pound, Lisa Kailai Han and Michelle Fox Theobald contributed reporting.This story originally appeared on: CNBC - Author:Sean Conlon